Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial.
David E J JonesMarco CarboneInvernizzi PietroNicola LittleFrederik NevensMark G SwainPhilippe WieselCynthia LevyPublished in: Hepatology communications (2023)
These results support further investigation of setanaxib as a treatment for patients with PBC, particularly for those with clinically significant fatigue.